Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Oral fluoropoyrimidines.

P M Hoff1, M Royce, D Medgyesy

  • 1Division of Medicine, The University of Texsas M.D. Anderson Cancer Center, Houston, TX 77030, USA.

Seminars in Oncology
|December 22, 1999
PubMed
Summary

Oral fluoropyrimidines offer a convenient alternative to intravenous 5-FU for colorectal cancer, potentially reducing toxicity and complications associated with infusion pumps and central lines.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

DESTINY-Gastric05 phase III trial of first-line trastuzumab deruxtecan, chemotherapy, and pembrolizumab in HER2-positive gastric or gastroesophageal junction cancer.

ESMO gastrointestinal oncology·2026
Same author

Modulation of GABAergic System in a Chicken Retinal Ischemic Model: The Role of Chloride Cotransporters.

Journal of neuroscience research·2025
Same author

Clinical presentation and in-hospital prognosis of lung cancer patients presenting with suspected and confirmed COVID-19.

Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas·2022
Same author

External control arms in oncology: current use and future directions.

Annals of oncology : official journal of the European Society for Medical Oncology·2022
Same author

Corrigendum to "Bringing safe and effective therapies to premenopausal women with breast cancer: efforts to broaden eligibility criteria": [Annals of Oncology 32 (2021) 950-953].

Annals of oncology : official journal of the European Society for Medical Oncology·2022
Same author

Bringing safe and effective therapies to premenopausal women with breast cancer: efforts to broaden eligibility criteria.

Annals of oncology : official journal of the European Society for Medical Oncology·2021

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Protracted intravenous fluorouracil (5-FU) improves colorectal cancer treatment outcomes but requires invasive central venous lines, risking thrombosis and infection.
  • Current oral 5-FU formulations suffer from erratic absorption due to dihydropyrimidine dehydrogenase (DPD) metabolism, limiting their clinical utility.

Purpose of the Study:

  • To explore oral fluoropyrimidine formulations as a viable alternative to intravenous 5-FU for colorectal cancer treatment.
  • To identify strategies for overcoming the challenges of oral 5-FU absorption and metabolism.

Main Methods:

  • Review of existing methods to circumvent gastrointestinal 5-FU metabolism by DPD.
  • Discussion of two primary strategies: DPD inactivation and the use of 5-FU prodrugs for enhanced absorption.

Main Results:

  • Oral fluoropyrimidines can achieve prolonged 5-FU exposure.
  • These agents demonstrate a reduced incidence of toxicity compared to traditional methods.

Conclusions:

  • Effective oral 5-FU formulations can offer a convenient and safer protracted treatment for colorectal cancer.
  • Prodrug strategies and DPD modulation hold promise for improving oral chemotherapy delivery.

Related Experiment Videos